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Abstract
Introduction: Patients with femur fracture benefit from early surgery. Recent reports suggest that regional anesthesia may be
superior to general anesthesia in these patients. Early surgery under spinal anesthesia could be performed safely by determining
platelet function in patients receiving antiplatelet agents.
Methods:Multicenter, randomized, open-label, parallel clinical trial expected to include 156 patients≥ 18 years of age under chronic
treatment with antiplatelet agents who develop a proximal femur fracture. Exclusion criteria: presence of multiple or pathological
fractures, current treatment with vitamin K antagonists or new oral anticoagulants, and congenital or acquired coagulopathy.
Patients will be randomized to either
1. a guided early surgery strategy in which preoperative platelet function will be assessed at emergency department admission or
2. a conventional strategy in which surgery under neuraxial anesthesia will be scheduled according to the margin of safety time
established for the specific antiplatelet agent.
The primary endpoint is time (hours) from admission to surgery. Secondary endpoints include: platelet function; postoperative
bleeding; medical-surgical complications; perioperative and 1-year mortality; quality of life; length of hospital stay; cost-effectiveness;
and cost-utility. Follow-up assessments will be performed during hospital admission and at 1, 6, and 12 months after surgery.
Potential impactof thestudy:The determination of platelet function at admission to the emergency department in patients with
femoral fracture receiving antiplatelet therapy may permit earlier surgery under spinal anesthesia, thus shortening the hospital stay
and reducing the risk of complications. These advantages associated with early surgery could positively impact patient well-being
and also reduce treatment-related healthcare costs.
Ethics anddissemination: The study has been approved by the ethics committees at all participating centers. Their results will
be disseminated in congresses and published in peer reviewed journals.
Abbreviations: ADP = Adenosin diphosphate, AFFEcT clinical trial = Ensayo clínico en pacientes Antiagregados con Fractura
proximal de Fémur que evalua una Estrategia para aCortar el Tiempo hasta la cirugía. Clinical trial in patients with Antiplatelet therapy
and a proximal Femur Fracture to assess a stratEgy to Cut the Time to surgery, ANOVA= ANalysis Of VAriance, ASA= AcetylSalicylic
Acid, DHS = Dynamic Hip Screw, EQ-5D-5L questionnaire = European Quality of life-5 Dimensions-5 Level scales questionnaire,
EQ-VAS questionnaire = European Quality of life-Visual Analogical Scale questionnaire, ERDF = European Regional Development
Fund, GRANMO calculator = GRANdaria de la MOstra calculator, ITT = Intention To Treat, PFA-100 system = Platelet Function
Assay -100 system, PTLwork= PlaTeLet work, QALYs= quality-adjusted life years, SAE= serious adverse event, SCReN= Spanish
Clinical REsearch Network, SD = standard deviation, SPIRIT = standard protocol items recommendations for interventional trials,
USA = United States of America.
Keywords: randomized clinical trial, platelet aggregation inhibitors, femoral fracture, platelet function
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1. Introduction
Femoral fractures in elderly patients are the most common cause
of admission to Orthopaedic Surgery and Traumatology
departments. Proximal femoral fractures account for approxi-
mately 42–50% of all fractures in the elderly population.[1]
Postoperative mortality rates in the first 30 days can be as high as
10% and range from 18–33% in the first year. Several patient-
related variables—including older age, males, dementia, and
frailty—are associated with higher mortality rates.[2–6] The
annual cost to the health care system of treating femoral fractures
is non-negligible, primarily due to high morbidity and mortality
rates.[7,8]
Clinical guidelines recommend that surgery be performed, if
feasible, within the first 48hours after fracture in order to reduce
perioperative complications and in-hospital morbidity and
mortality.[9,10] Although studies have shown that early surgery
is beneficial for patients on chronic antiplatelet therapy,[11] these
patients must undergo general anesthesia because neuraxial
anesthesia is contraindicated.[12–15] The choice of anesthetic
technique in patients with femoral fracture is controversial due to
influence of the anesthetic technique on postoperative morbidity
and mortality. Based on recent data, neuraxial anesthesia yields
lower in-hospital mortality rates and shorter hospital stays than
general anesthesia in patients with femoral fracture.[16,17]
However, more evidence is needed to definitively resolve this
debate. In this regard, 2 clinical trials are currently underway to
compare these 2 anesthetic techniques.[18,19]
Some clinical guidelines recommend platelet function testing
to shorten the time from admission to surgery in patients
who undergo neuraxial anesthesia.[20,21] In patients
receiving chronic antiplatelet treatment, the use of these tests
to determine the number of functional platelets is crucial to
ensure that early surgery with neuraxial anesthesia can be
performed safely.
In this context, we have designed a randomized clinical trial to
evaluate the safety and efficiency of a therapeutic strategy
involving preoperative determination of platelet function in
patients with femoral fracture receiving chronic antiplatelet
treatment. The main objective of this trial is determined whether
this strategy, designed to reduce the time from admission to
surgery under spinal anesthesia, provides any benefits compared
to a conventional strategy based on delayed surgery after
discontinuation of antiplatelet therapy.
2. Methods
The study protocol (version 3, code IIBSP-PLA-2016–86) was
developed in accordance with the SPIRIT recommendations for
interventional trials.[22] The present randomized controlled trial
was approved by the ethics committees of all participating centers
and registered at clinical trials.gov (NCT03231787).
2.1. Study design
Multicenter, randomized, open-label, parallel clinical trial of
patients receiving chronic antiplatelet therapy admitted to the
emergency department with a femoral fracture. All study
participants will undergo platelet function testing and those with
more than 80,000 functional platelets will be randomized to either
early surgery with neuraxial anesthesia or delayed surgery with
neuraxial anesthesia performed in accordancewith the antiplatelet
activity time of the specific antiplatelet drug (3 days for aspirin 300
mg/day and triflusal 600mg/day; 5 days for clopidogrel and
ticagrelor; 7 days for prasugrel, and 10 days for ticlopidine).
Recruitment started in September 2017 and will continue until
December 2019. The last follow-up visit for the final patient
included in the study will be in December 2020. To date, 81
patients have been included.
2.2. Objectives
2.2.1. Primary. To compare the time in days from hospital
admission until surgery in the 2 groups.
2.2.2. Secondary. To check for difference between the 2 groups
in the following variables: postoperative bleeding, medical and
surgical complications, length of hospital stay, quality of life,
mortality, cost-effectiveness, and cost-utility.
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Agreement between the 2 different platelet function assays (see
Methods) will be assessed in a subset of 20 patients.
2.3. Participants
2.3.1. Study location. The following 4 centers will participate in
this study: Hospital de la Santa Creu and Sant Pau, Althaia-
Xarxa Assistencial Universitària de Manresa,Vall d’Hebron
Hospital, and Hospital Clinic of Barcelona (Spain).
2.3.2. Inclusion criteria. Study inclusion criteria:
(1) adults (male or female) ≥ 18 years of age;
(2) diagnosis of femoral fracture; and
(3) receiving treatment with antiplatelet agents (acetylsalicylic
acid [ASA] > 100mg/d; triflusal > 300mg/d; clopidogrel;
prasugrel; ticagrelor; or ticlopidine) at admission to the
emergency department.
Written informed consent will be obtained from all patients.
2.3.3. Exclusion criteria. Exclusion criteria: presence of multi-
ple or pathological fractures, current treatment with vitamin K
antagonists or new oral anticoagulants, and congenital or
acquired coagulopathy.
2.3.4. Criteria for withdrawal from the clinical trial. The
emergence of any of the following events may justify study
withdrawal: severe adverse event, any clinical condition
preventing the patient from continuing in the trial, protocol
violations, the patient’s voluntary decision to withdraw, loss to
follow-up, or death.
2.4. Outcomes and measures
2.4.1. Main outcome. Time, in hours, from emergency room
admission until surgery.
2.4.2. Secondary outcomes. Clinical: postoperative bleeding,
complications associated with the surgical procedure and surgical
wound, medical complications during admission, perioperative
mortality and mortality at 1 year, quality of life (EQ-5D-5L
generic questionnaire) assessed preoperatively and postopera-
tively at days 5 and 30 and months 6 and 12.
Costs: length of hospital stay, surgery-associated direct health
costs, laboratory tests, medications, consumables, complemen-
tary diagnostic tests, resources required to treat perioperative
complications, cost associated with rehabilitation, consultations
with specialists, and primary care visits after hospital discharge
and during follow-up.
A subgroup analysis of 20 consecutive patients from one of the
participating centers will be performed to determine the
correlation between 2 platelet function systems (PlaTeLet work
[PTLwork] versus the conventional Platelet Function Assay [PFA-
100 system]).
2.4.3. Patient follow-up. Follow-up visits will be conducted
during hospitalization, and postoperatively by phone at months
1, 6, and 12.
2.5. Randomization and allocation of interventions
A computer-generated permuted block randomization sequence,
stratified by center, will be used for the randomization process. A
web-based platform (www.clipnasis.com) will be used to allocate
patients to the interventions. This platform will randomly assign
a number to each patient and to the corresponding intervention.
Researchers will be blinded to the allocation sequence of the
study interventions.
2.6. Blinding
Necessarily, the patients and researchers will know which
intervention they have been allocated. However, to avoid
influencing the timing of the surgical procedure, the investigators
will be blinded to the platelet function status in the control group.
2.7. Implementation and data collection
Figure 1 describes the patient recruitment process and the study
plan. A competitive recruitment process will be used; thus, no
predetermined limit to the total number of patients per center has
been established. Patient selection will be performed on the day of
admission to the hospital emergency department. Researchers
will first verify that the patient meets the study inclusion criteria.
The patient will then be informed about the clinical trial and
asked to participate. Patients who agree to participate will be
enrolled in the study after signing the informed consent form.
Next, they will be randomized to one of the 2 study groups.
Blood samples will be taken at the time points established in the
study and analyzed in the laboratory within 10 minutes of
extraction to determine platelet function. Platelet function will be
performed in all patients using the PFA-100 system (Siemens,
Munich, Germany). This system is based on the adhesion
properties of platelets when subjected to stress conditions and in
the presence of a particular agonist. The citrated whole blood is
conducted through a capillary to a collagen membrane with a
microscopic opening (147mm) covered by an agonist (adenosine
diphosphate [ADP] or epinephrine). The system determines the
time it takes for the hole to close (closure time).
In a small subset of patients (n=20), the PTLwork system
(Helena Laboratories, Beaumont, TX) will also be used to
determine preoperative platelet function. This 2-step system
determines the number of platelets added and/or inhibited. In the
first step, the total platelets are counted in a blood sample. Next, a
second sample containing a platelet agonist (ADP or collagen) is
examined to count the number of non-functional platelets. The
difference between the 2 platelet counts yields the number of
functioning platelets.[23]
The key outcome variables of this clinical trial (date and time of
admission; date and time of surgery; blood loss; transfusion units;
and complications) will be obtained from patient medical records
and by direct patient interview (in person and/or by telephone).
The collected information will be uploaded to a password-
protected electronic web-based database (http://www.clinapsis.
com).
2.8. Interventions
2.8.1. Experimental intervention. At emergency room admis-
sion, the antiplatelet medication will be discontinued and platelet
function will be determined. In patients with >80,000 functional
platelets, the surgery will be scheduled within the next 24hours.
However, if the level of functional platelets is <80,000, then the
platelet assay will be performed once per day for the next 2 days
or until normalized (whichever occurs first): surgery will be
performed within 24hours after normalization. If the number of
functional platelets has not normalized after 3 days, surgery with
neuraxial anesthesia will be scheduled in accordance to the
margin of safety time established for the specific antiplatelet
medication.
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2.8.2. Control intervention. Antiplatelet therapy will be
discontinued at admission to the emergency room. Surgery
with neuraxial anesthesia will be performed in accordance with
the established safety time for the antiplatelet drug. Platelet
function will be determined the day before surgery but the
results will not be revealed to the researchers until the end of the
study.
2.8.3. Co-intervention. All included patients must be eligible for
neuraxial anesthesia.
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n=78 
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Blinded test 24h before surgery
<80000 
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Figure 1. Flowchart of the clinical trial.
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2.8.4. Description of the surgical intervention. The specific
surgical technique—osteosynthesis, hemiarthroplasty, or total
hip arthroplasty—will depend on the characteristics of the
proximal femur fracture in each patient. Osteosynthesis will be
performed with cannulated screws, Dynamic Hip Screw with
plate (DHS), or intramedullary nail (short or long), depending on
the fracture type. Displaced subcapital fractures will be treated by
hemiarthroplasty (monopolar or bipolar) or total hip arthro-
plasty, depending on the patient characteristics. Total arthro-
plasty can be cemented, uncemented, or hybrid. In all cases, the
orthopedic surgeon will follow the surgical protocol in place at
the treating hospital for the type of fracture. Each center will
follow the specific transfusion protocol in place at that
institution.
2.9. Statistics
2.9.1. Sample size estimation.One of the participating centers
used historical data from the hospital database to calculate the
mean time from admission to surgical intervention in patients not
receiving antiplatelet treatment and without any coagulopathies:
2.85 days (standard deviation [SD], 3.17). Accepting an alpha
risk of 0.05 and a beta risk under 0.20 in a 2-sided contrast and a
10% loss rate, the estimated sample size needed to detect a
decrease of≥1.5 days from admission to surgery was 156 patients
(78 subjects in the experimental and control groups, respectively).
This calculation was made using v. 7.10 (June 2010) of the
GRANMO calculator (available at: https://www.imim.es/oferta
deserveis/en_granmo.html).
2.9.2. Data analysis. The main analysis of efficacy will be made
“per protocol”, but ananalysis onan Intention-ToTreat (ITT)basis
will be done to test the consistency of the results. In the “per
protocol” analysis will be included patients that have received the
corresponding test for platelet function and have been undergoing
surgery. In the ITT,analysiswill be includedall patients randomized
independently if they have received the test or the surgery.
The 2 groups will be compared to ensure that there are no
significant differences in the clinical variables of interest.
Student’s t test will be applied to check for between-group
differences in the main study endpoint (mean time from
admission to surgery). The specific statistical analysis of the
baseline characteristics will depend on the nature of the evaluated
variables. For categorical variables, we will use the chi-square test
with the corresponding contingency table. Ordinal or quantita-
tive variables with clear non-normal distribution will be analyzed
using the nonparametric test for more than 2 groups (Kruskall-
Wallis), including medians with ranges for each group. The t test
will be used to assess quantitative variables that meet normality
criteria, with mean values and SD provided for each group.
All variables showing statistically significant or clinically
relevant differences between the groups on the initial comparison
will be entered into a multivariate model to confirm that the
differences relative to the study’s main endpoint remain
significant on an analysis of covariance.
The EQ-5D-5L measures 5 dimensions (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression) related
to quality of life. Each dimension has 5 levels of severity (no
problems, slight problems, moderate problems, severe problems,
and extreme problems) which are scored from 1 (no problems) to
5 (extreme problems) points, with the maximum score of 1
indicating a state of full health. The partial results on each
dimension and the overall score will be calculated using the
scoring algorithms developed by Ramos-Goñi et al.[24] Because
this questionnaire yields ordinal data, nonparametric tests will be
used to analyze the comparisons. Between-group differences will
be analyzed using the Mann-Whitney and Kruskal-Wallis tests.
The EQ-VAS evaluates patient-perceived health status. This is
a vertical scale ranging from 0 to 100. An ANalysis Of VAriance
(ANOVA) will be performed.
For the economic analysis, we will calculate the costs in Euros
(€) based on the prices of the local health system. For the cost-
effectiveness analysis, the costs of the study intervention will be
compared to the incremental results, measured in natural units.
Cost-effectiveness will be measured by the time from hospital
admission to first mobilization after surgery. If the results in the 2
groups are similar, we will perform a cost minimization analysis.
Data will be converted into a unit-cost evaluation to determine
average cost per patient. We will conduct a comparative
economic evaluation of the 2 study alternatives. Confidence
intervals will be used to determine the presence of significant
differences.
To perform the cost-utility analysis, we will assess Quality-
Adjusted Life Years (QALYs)—measured with the EQ-5D-5L—
and cost per QALY, calculated incrementally (D cost/D QALYs)
in each group.
We will perform a deterministic sensitivity analysis to evaluate
the robustness of the results. The level of significance for all
statistical analyses will be set at 5%. The SPSS statistical software
program (v. 24) will be used to perform the statistical analyses.
2.10. Serious adverse event (SAE)
The organization of the study has established a circuit of
notification for serious adverse events. An SAE is defined as any
adverse event that:
1. causes the death of the patient;
2. is considered life-threatening;
3. requires hospitalization;
4. prolongs an existing hospitalization;
5. causes permanent or significant disability; or
6. causes an abnormality or congenital malformation.
2.11. Data monitoring
The study will be monitored by the Spanish Clinical Research
Network (SCReN) which is a public organization independent
from the sponsor and researchers to ensure the following:
appropriate inclusion of patients, availability of the informed
consent form for all patients, protocol adherence of the
researchers, and the application of standards of good practice
in research in each center. At least 3 visits per center have been
planned.
2.12. Ethics and dissemination
This trial will be conducted in accordance with the latest revision
of the Declaration of Helsinki governing standards for good
clinical practice.
All patients will be providedwith a detailed, easy to understand
(i.e., non-technical) written and oral explanation about the
nature, scope, and possible consequences of participation in this
trial. All patients will be required to provide written informed
consent to participate. All patients will receive a document with
Rafael et al. Medicine (2019) 98:19 www.md-journal.com
5
detailed information about the trial. Patient confidentiality will
be guaranteed because the data will be de-identified. This study
has been approved by the scientific research ethics committees at
all participating hospitals.
There is a policy insurance that cover patients for any adverse
event during the study.
The protocol has been presented at national and international
conferences. The results of the clinical trial will be published
independently and transparently, regardless of the results. The
authors of the publication will be the same researchers who have
participated in the design and/or execution of the study.
3. Discussion
This clinical trial will assess the efficacy and cost-effectiveness of
platelet-function monitoring to enable earlier surgery for femoral
fracture patients on chronic antiplatelet drugs under spinal
anesthesia. This trial will also determine the impact of this
treatment strategyon the lengthofhospital stay andcomplications.
Femur fractures require urgent surgical treatment, preferably
within 48hours.[9] If the fracture is not treated within this period,
research shows that there may be a substantial increase in
morbidity and mortality rates, length of hospital stay, and
healthcare costs.[3,5,18–20]
A range of different antiplatelet agents are available. Inter-
individual variability in response to the effects of these drugs is
high, particularly for bleeding. For this reason, the risk of
hemorrhage should be evaluated on an individual basis. Most
patients with a proximal femur fracture are elderly and
polypharmacy in these patients is common, potentially causing
gastrointestinal absorption disorders, metabolism alterations,
and drug interactions. As a consequence of polypharmacy,
platelet function may be normal in some patients on antiplatelet
therapy due to interactions with other drugs.
After discontinuation of antiplatelet therapy, invasive surgical
procedures must be postponed until functional platelet levels
have recovered. However, the time required to ensure a sufficient
margin of safety depends on the pharmacokinetics of the
particular medication. Neuraxial anesthesia is contraindicated
in patients on antiplatelet therapy in whom early surgery is
indicated but whose platelet function is unknown. The usual
approach in these patients is to perform surgery under general
anesthesia. However, a recent study involving patients with
femoral fracture found that, compared to neuraxial anesthesia,
general anesthesia was associated with higher rates of in-hospital
mortality and a longer hospital stay, but without significant
differences in mortality at 30 days after surgery.[16] Nevertheless,
more studies are required to confirm those findings.
Given the risks of general anesthesia in these patients, there is a
growing interest in the use of platelet function testing, as
evidenced by recent clinical guidelines suggesting that physicians
should consider using these tests in selected patients.[14] The value
of determining preoperative platelet function is to optimize the
timing and safety of early surgery under spinal anesthesia.
Few studies have assessed the effect of early surgery on
proximal femur fracture in patients on chronic antiplatelet
therapy. Nevertheless, the available evidence shows that patients
receiving chronic antiplatelet medications who undergo early
surgery present lower postoperative hemoglobin levels (around 1
g/L) than patients in which surgery is delayed, suggesting that
patients on antiplatelet therapy experienced a greater amount of
blood loss.[25,26] However, the findings of those studies must be
interpreted cautiously given the relatively small sample sizes
(<50 patients) and thus limited statistical power to identify
significant and clinically relevant differences. One randomized
clinical trial measured platelet function in patients with and
without antiplatelet drugs, but did not use these data to determine
whether early surgery was indicated or not.[27]
To our knowledge, the present study is the first randomized
clinical trial to assess a strategy based on determining platelet
function in order to reduce the time from admission to surgery
under spinal anesthesia in patients with femur fracture. In this
study, we will assess patient quality of life and also conduct cost-
effectiveness and cost-utility analyses to determine the impact of
this strategy on these variables. In addition, we will compare the
PLTwork and PFA-100 systems to assess their level of agreement.
Themain limitation of this trial is the lack of treatment blinding. A
second limitation is that only an exploratory analysis of secondary
outcomes (morbidity and mortality) will be performed.
4. Conclusions
Determining preoperative platelet function in patients on chronic
antiplatelet therapy may shorten the time from emergency
department admission to surgery with regional anesthesia. This
individualized approach may increase the safety of the surgical
procedure by minimizing the risk of bleeding and anesthesia-
related complications.
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